CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment - PubMed (original) (raw)

. 2010 Nov 15;25(15):2682-5.

doi: 10.1002/mds.23287.

Min Shi, Joseph F Quinn, Elaine R Peskind, Suzanne Craft, Carmen Ginghina, Kathryn A Chung, Hojoong Kim, Douglas R Galasko, Joseph Jankovic, Cyrus P Zabetian, James B Leverenz, Jing Zhang

Affiliations

CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment

Thomas J Montine et al. Mov Disord. 2010.

Abstract

We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF Aβ(42), total tau (T-tau), and phospho-tau (P181-tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls ≤50 years (35), Controls >50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Aβ(42) was reduced in PD-CIND (P < 0.05) and PD-D (P < 0.01), whereas average CSF T-tau and P181-tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Aβ(42) may be a common feature of PD-CIND and PD-D.

© 2010 Movement Disorder Society.

PubMed Disclaimer

Figures

Figure 1

Figure 1. Scatter plots of CSF Aβ42 and P181-tau concentrations

Individuals’ CSF Aβ42 and P181-tau concentrations for (A) both Control groups, subjects with amnestic Mild Cognitive Impairment (MCI), and patients with Alzheimer’s Disease (AD), and for (B) patients with Parkinson’s disease (PD) without cognitive impairment (CI), with CI but Not Dementia (PD-CIND), or dementia (PD-D).

Similar articles

Cited by

References

    1. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–194. - PubMed
    1. Sonnen JA, Montine KS, Quinn JF, Kaye JA, Breitner JC, Montine TJ. Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol. 2008;7:704–714. - PMC - PubMed
    1. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403–413. - PMC - PubMed
    1. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385–393. - PubMed
    1. Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69:631–639. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources